A total of 61 consecutive adult patients with haematological malignancies with an HLA-identical or one antigenmismatched haploidentical family donor were randomised to allogeneic transplantation with blood stem cells (BSC) or bone marrow (BM). The median observation time was 5 years. Apart from engraftment parameters and acute graft-versus-host disease (GVHD), transplant-related mortality (TRM), incidence and severity of chronic GVHD, relapse, leukaemia-free survival (LFS) and overall survival (OS) were recorded. In the BSC and BM group, respectively, TRM was 8/30 and 4/30 (P ¼ 0.405), the incidence of chronic GVHD was 15/26 and 11/30 (P ¼ 0.138), extensive chronic GVHD was 10/26 and 4/30 (P ¼ 0.034), and relapse one and 10 patients (P ¼ 0.007). In log-rank test restricted to the cases allografted from HLA-identical donors, the difference remained significant with regard to relapse incidence (P ¼ 0.039), but not extensive chronic GVHD (P ¼ 0.072). No difference in LFS and OS was observed. In conclusion, our study strongly indicates an enhanced graft-versus-leukaemia effect in BSC recipients, which is not expressed in increased survival. The increased chronic GVHD in these patients may contribute, but the relation is complex and not yet understood. Despite a high number of T lymphocytes in BSC allografts, there is little evidence of an increased incidence of acute GVHD. This could be because of the modulation of T cell cytokine expression towards a Th-2/Tc-2 (noncytotoxic) phenotype with anti-inflammatory functions induced by G-CSF.
Randomised
1-8 and nonrandomised 9 trials have shown a significantly shorter period of aplasia using blood stem cells (BSC) compared to bone marrow (BM) in allogeneic stem cell transplantation, and BSC allografts reduce the requirements for platelets and antibiotics. 6 Despite a high number of T lymphocytes in BSC allografts, there is little evidence of an increased incidence of acute GVHD. This could be because of the modulation of T cell cytokine expression towards a Th-2/Tc-2 (noncytotoxic) phenotype with anti-inflammatory functions induced by G-CSF. 10, 11 However, the results are not fully consistent since one of the largest studies revealed a significantly higher incidence of acute GVHD, possibly explained by the omission of the methotrexate dose on day +11. 1 There are indications that BSC allografts are more likely to reduce TRM. A Canadian randomised study showed a significant reduction in nonrelapse mortality at 30 months in the BSC group compared to BM. 7 Furthermore, a nonrandomised, retrospective study showed a significant difference in 1-year TRM in favour of BSC allografting in advanced leukaemia. 9 Several retrospective and nonrandomised studies indicate that the incidence of chronic GVHD might be increased after BSC allografting. [12] [13] [14] [15] [16] [17] Two randomised studies showed a significantly higher overall incidence of chronic GVHD and, in particular, extensive chronic GVHD in BSC-transplanted patients, 18, 19 in contrast to larger randomised studies. 1, 20 On the other hand, currently there is no evidence that an increased incidence of chronic GVHD causes a higher late mortality rate. Analyses of the impact on long-term quality of life are lacking.
It is well established that the occurrence of GVHD and GVL is strongly correlated. 21 Given an increased incidence of chronic GVHD following BSC allografting, a reduced relapse rate in patients may be anticipated. This notion is supported by one prospective randomised trial in CML, 22 and by a few nonrandomised studies. [23] [24] [25] Several authors have reviewed the available randomised studies. [26] [27] [28] [29] [30] They conclude that a longer follow-up is required to establish the role of BSC allografts in terms of long-term haematopoietic reconstitution, chronic GVHD, late transplant-related mortality (TRM), relapse rate and overall survival (OS).
We present the results of a 5-year follow-up of the first single centre prospective randomised trial comparing BSC and BM allogeneic transplantation, with special attention to chronic GVHD, TRM, relapse rate, leukaemia-free survival (LFS) and OS.
Subjects and methods

Definitions
TRM is defined as treatment-related death, irrespective of the time after transplantation. Relapse of acute leukaemia shall mean extramedullary leukaemia and/or more than 5% blasts in a BM smear with normal cellularity. In patients with CML, relapse is defined as cytogenetic relapse. A positive bcr-abl-PCR is not considered as relapse. LFS is measured as the number of days from transplantation until death or the first manifestation of relapse. OS is measured as the number of days from transplantation until death.
Patients
From June 1994 until February 1999, 61 patients were randomised to either transplantation with BSC or BM, 31 and 30 patients, respectively. One patient in the BSC group was excluded. The results from this trial were first published in 2000. 6 Patient characteristics are summarised in Table 1 . The following criteria of risk of relapse were used: an unfavourable cytogenetic profile, 31, 32 the need for additional induction treatment defined as delayed response to induction therapy, and finally, patients with acute leukaemia beyond one CR, MDS and secondary AML defined as advanced disease at the time of transplantation. The number of patients with one risk factor or more is showed in Table 1, while Table 2 describes the risk factor in question for each individual patient. Three patients had 
Harvest procedures
The harvest procedures have been described previously. 6, 33 A minimum of 2 Â 10 6 CD34 + cells/kg recipient body weight (bw) was required for BSC transplantation, and a minimum of 2 Â 10 8 nucleated cells (TNC)/kg recipient bw was required for BM transplantation. Graft characteristics are presented in Table 3 . 34 
Conditioning and GVHD prophylaxis
All patients were conditioned with busulphan (16 mg/kg) and cyclophosphamide (120 mg/kg) as described. 7 Intrathecal methotrexate (MTX) 12 mg/day was given to patients with AML (FAB classification M4/M5) or ALL on days À8 and À4 and four times after transplantation. TBI, CNS radiation and T cell depletion were not parts of the conditioning regimen in any patient.
GVHD prophylaxis consisted of cyclosporin A (CsA) from day À1 and tapered from day+180 unless there were clinical signs of chronic GVHD. In addition, MTX was administered i.v. 15 mg/m 2 on day+1 and 10 mg/m 2 on days +3,+6 and +11 providing there were no signs of serious liver toxicity. Acute GVHD was graded continuously according to the Glucksberg criteria. 35 Chronic GVHD was classified as described by Shulman et al.
36
Supportive care
Supportive care consisted of prophylactic administration of acyclovir from day À2 until day +28. The patients were given co-trimoxazol (TMS) for 2 weeks and until day À4. When neutrophils exceeded 1.0 Â 10 9 /l and platelets 50 Â 10 9 /l, TMS was given as pneumocystis carinii prophylaxis until day +180, or longer if immunosuppressive treatment for chronic GVHD was given. Patients were not given G-CSF post transplant.
Study design and statistical analysis
The 61 patients were stratified according to age, but not to HLA mismatch, stage of the disease or other prognostic factors. Subsequently, they were randomised in blocks of six, three for each type of cell harvest. We applied parametric methods (t-tests) to compare different groups. Categorical data were analysed with w 2 tests or Fisher's exact tests. Competing risk outcomes such as chronic extensive GVHD and relapse were visualised with cumulative incidence curves. 37 Survival data were visualised with Kaplan-Meier survival curves. 38 Comparisons of survival were performed with log-rank tests. Cox models were used to study the effect of several variables on extensive chronic GVHD and relapse. Two-sided P-values less than 0.05 were considered as statistically significant.
The algorithms in SPSS 10.0 (SPSS, Chicago, IL, USA) and Splus (Insightful, Seattle, WA, USA) were used to perform the statistical analysis.
Written informed consent was obtained according to protocols approved by the Regional Committee for Medical Research Ethics, Southern Norway (REC II).
Results
Chronic GVHD and morbidity
In total, 26 patients in the BSC arm and 30 patients in the BM arm were evaluable for chronic GVHD, having survived 3 months. The number of patients developing chronic GVHD was 15 in the BSC group (57.7 %) and 11 (36.7 %) in the BM group (P ¼ 0.138). Extensive chronic GVHD was found in 10 (38.5 %) and four patients (13.3 %), respectively (P ¼ 0.034). However, a log-rank test restricted to the cases allografted from HLA-identical donors did not show any significant difference between the groups (P ¼ 0.072), and the corresponding cumulative incidence curves are shown in Figure 1 . A multivariate analysis of factors affecting extensive chronic GVHD showed that HLA mismatch was the most important factor At 3 years post transplant, 12 patients suffered from chronic GVHD in the BSC group, two patients had died because of GVHD-related complications and in one patient GVHD had resolved. In the BM group, seven patients suffered from chronic GVHD, two patients had died because of chronic GVHD and two patients had recovered completely. One of these patients died of obliterative bronchiolitis after 4 years. No patient developed chronic GVHD after 3 years. At the last follow-up at 4 years post transplant, GVHD had resolved in another patient in the BSC group.
Among the BSC recipients, there were 10 patients with extensive GVHD. Four of them had obliterative bronchiolitis, and three of these patients had an HLA-mismatched donor. In the BM group, only four patients had extensive GVHD, one of whom suffered from obliterative bronchiolitis. This patient was the only recipient of an HLAmismatched allograft in the BM group. A detailed characterisation of the patients with extensive chronic GVHD is presented in Tables 4 and 5 .
In patients with limited chronic GVHD, CsA was continued and gradually tapered. In some cases of extensive chronic GVHD, the condition required steroids and other immunosuppressive agents. Patients with obliterative bronchiolitis were, in addition, given cimetidine without any convincing effect.
Among the BSC recipients, one patient has developed cancer of the breast 5 years post transplant. In the BM group, there were two cases of secondary malignancy. One developed basocellular carcinoma of the skin, another, Epstein-Barr virus associated non-Hodgkin's lymphoma. A third patient acquired a probable malignant melanoma in the choroidea. Prior to the outbreak of secondary cancer they all had chronic GVHD, except for the patient with the eye condition.
Hypothyroidism developing after stem cell transplantation has not been diagnosed in any of the patients.
TRM
A total of 30 patients in each group were evaluable. In the BSC group, eight patients (26.7%) died of treatmentrelated conditions, four (13.3%) in the BM group. The probability of TRM is shown in Figure 2 . The difference between the groups is not statistically significant (P ¼ 0.405). The causes of transplant-related death until August 1999 have been published in a previous paper. 7 Since then four patients have died of treatment-related conditions, three in BSC treatment arm. A male patient died 472 days after transplantation of chronic GVHD and Probability of TRM 
Relapse, LFS and OS
The cumulative incidence curves for relapse are shown in Figure 3 . The difference between the groups is statistically significant (P ¼ 0.007). A log-rank test restricted to the cases allografted from HLA-identical donors shows significantly reduced relapse rate among the BSC allografted (P ¼ 0.039). A multivariate analysis of factors affecting relapse showed that high-risk disease was the only factor associated with significantly increased relapse incidence (P ¼ 0.005) in addition to the stem cell source.
In the BSC group, only one male patient relapsed (Table 6 ). His AML was classified to represent standard risk. He had a chromosome 2 abnormality not considered unfavourable. He did not develop chronic GVHD. Among the 11 patients with high-risk leukaemia, five patients have developed chronic GVHD.
In the BM group 10 patients relapsed, eight of these were considered as high risk for relapse (Table 6) . Among the 13 patients with high-risk leukaemia, three patients have developed chronic GVHD. Two of the relapsed patients had CML classified to represent standard risk. One of these patients received donor lymphocyte infusions (DLI) in combination with interferon. At last follow-up he was in complete haematological, cytogenetic and molecular remission. The other patient had positive bcr/abl transcripts by nested-PCR all the time since transplantation. At 5 years post transplant, she relapsed cytogenetically and is now treated with DLI. A female patient with ALL in second remission relapsed 2 years post transplant. She obtained complete haematological remission, which lasted 2 years after reinduction with cytotoxic agents. A male patient transplanted with AML in early first relapse was treated with DLI unsuccessfully when he relapsed after 4 months. None of the relapsed patients developed chronic GVHD. Except for the two patients with CML, all the relapsed patients have died. Finally, a patient with CML transplanted in the first chronic phase had a molecular relapse with a positive bcr-abl-PCR at 3 years post transplant, but is still in cytogenetic and haematological remission without any treatment. This patient is not counted among the relapses in the BM group.
The Kaplan-Meier survival curve for LFS is shown in Figure 4 . The difference between the groups was not 
Discussion
This long-term follow-up supports previous reports that there is a significantly higher incidence of extensive chronic GVHD among recipients of BSC as compared to BM. [12] [13] [14] [15] [16] [17] [18] [19] Our patient population has an unequal distribution of HLA-mismatched pairs that in part explains the difference. This is disclosed by the log-rank test where the HLAmismatched pairs were excluded. There are also more male recipients with a female donor in the BSC group. This is regarded as an important risk factor for chronic GVHD, 39, 40 but is not supported by the multivariate analysis of our data. In the BSC group there are nine male recipients with a female donor, of whom four developed chronic GVHD. Seven of 13 male recipients with a male donor developed chronic GVHD. Older age of the recipient is an independent risk factor for chronic GVHD. 40 In our cohort the BSC patients are slightly younger than BM recipients, which possibly could reduce the risk. Some authors suggest an association between low number of CD34 + cell number with higher T cell number in the graft and chronic GVHD. 26 Other authors state that a CD34 + cell dose below 8 Â 10 6 /kg recipient bw is associated with a decreased risk of developing clinical extensive chronic GVHD, compared to higher doses. 41 Our BSC patients received a median of 3.1 Â 10 6 /kg recipient bw, which was sufficient for an early engraftment, but the effect on GVHD is uncertain. We conclude that the heterogeneity between the treatment groups and the small number of patients reduces the power of statistical analysis related to extensive chronic GVHD, even if the trend is clear. Supportive evidence comes from the multivariate analysis of our data, which showed that the stem cell source is the most important predictor for developing extensive chronic GVHD next to HLA mismatch.
It has been suggested that the strongest predicting factor for secondary malignancies is chronic GVHD. 42 Since BSC allografting is associated with more chronic GVHD, one would expect a higher incidence of secondary malignant neoplasm among the recipients of BSC. This notion is not supported by our study. A longer follow-up may change this picture.
Does more extensive chronic GVHD lead to higher TRM in recipients of BSC? Randomised studies do not support this hypothesis. On the contrary, many studies show a trend towards a lower TRM in recipients of BSC allografts, and one randomised study shows a significantly reduced TRM in the BSC group. 7 One retrospective study shows significantly lower 1-year TRM after BSC transplants in patients with advanced leukaemia, probably because of the rapid engraftment reducing the risk for severe infections and haemorrhages. 9 Our study shows no significant difference between BSC and BM allografting. However, the study was not designed to address this question. The higher incidence of chronic GVHD may have a negative impact on late TRM among the BSC patients. Longer follow-up studies are needed.
As the presence of chronic GVHD is strongly associated with increased GVL-effect, it has been expected that BSC allografting would reduce the relapse rate compared to BM. 43, 44 The randomised trials are presenting diverging results and are therefore not conclusive. One small randomised study showed a significantly lower risk of relapse in BSC recipients. 5 Other studies show a trend towards lower relapse rate after BSC allografting only in patients with advanced leukaemia. 8, 9 In two randomised studies with patients in early-stage leukaemia, the LFS was identical in the two groups. 1, 4 Our study shows a significantly lower relapse incidence in BSC recipients. Patients considered high-risk are equally distributed between the groups. Among the 11 high-risk patients in the BSC group, there were five patients with chronic GVHD and no relapse occurred. In the BM group, the corresponding numbers were 13 and three, and eight patients relapsed. These data support the hypothesis that an enhanced GVL effect is provided by BSC allografts, an effect that may exist without clinically overt chronic GVHD. 45 The slightly higher number of high-risk patients in the BM group cannot fully explain the difference between the groups, and for this reason, the stem cell source seems to be a crucial factor. Nevertheless, the study did not show any statistically significant difference between the groups regarding LFS, which could be explained by the relatively higher TRM (eight patients in the BSC group vs four in the BM group) annulling the lower relapse mortality in the BSC group.
With regard to OS, BSC recipients with advanced leukaemia appeared to have a benefit over BM as shown in the large retrospective IBMTR/EBMT study. 9 In the Canadian randomised trial, there was a significant difference in OS at 30 months favouring patients randomised to BSC allografting. 7 Our trial does not reveal any significant difference between the BSC and BM recipients. Higher incidence of chronic GVHD implies more morbidity with a higher risk of late TRM among BSC patients. On the other hand, reduced relapse rate has an opposite effect on survival. Longer follow-up of our and patients from other randomised studies is necessary to assess this key end point.
Regarding donors, previous studies of safety and complaints have shown that BSC harvest is the best method of collecting stem cells providing no unexpected long-term detrimental consequences will emerge. 33, 46, 47 In addition, BSC allografting is at least cost equivalent to allogeneic BM transplantation as suggested in a Canadian and a French trial. 48, 4 Thus, the choice of stem cell source should mainly depend on what is regarded as most favourable to the recipient. The relatively high incidence of extensive chronic GVHD is an important reservation against the uncritical use of BSC in allogeneic sibling donor transplantation, at least in low-risk and standard risk patients. Several of the BSC recipients with standard-risk leukaemia in our study developed chronic GVHD. They were probably not in need of this potentially mutilating condition to evade relapse. It is our opinion that at the present time, BSC should be reserved for patients with advanced disease. An alternative approach to improve the effect of BSC is to selectively strengthen the immunosuppressive treatment in patients with standard-risk leukaemia. However, this may reduce the beneficial GVL-effect. Other pharmacotherapeutic approaches are investigated. 49 Graft engineering by some kind of T cell depletion and/or CD34 + selection is another approach. Humanised CD52 antibodies have been used with encouraging results. 50 Recently, it has been suggested that a higher number of mesenchymal cells in the graft could facilitate engraftment and prevent GVHD. 51, 52 In conclusion, long-term follow-up of our patients shows a trend towards increased incidence of extensive chronic GVHD, resulting in increased, but so far not statistically significant higher TRM in patients allografted with BSC compared to BM. On the other hand, BSC transplantation seems to result in a stronger GVL effect with a subsequent reduced relapse rate, but without a significant impact on the leukaemia-free survival and the OS. Patients with highrisk leukaemia may nevertheless have benefit from the use of BSC, while BM may give the most favourable outcome for patients with low-and standard-risk leukaemia. The clinical practice in our centre has been changed accordingly and implemented since year 2000.
